# Adjusted Llama vs Gemini Audit

Source report: `llm_explainer/llama_vs_gemini_azd7762_a204_8b.md`

## How To Read This

- **Strict pass** keeps the original machine-contract rule: exactly 3 sentences, exact tag spelling, no unsupported Evidence tags, no new numbers.
- **Adjusted status** separates presentation interpretation from strict formatting. Entrez suffixes in Evidence tags are normalized, and sentence-count mistakes become format warnings.
- Degraded conditions still fail if the model confidently rationalizes shuffled features or the wrong-drug setup.

## Adjusted Summary

| Condition | Model | Strict Pass | Adjusted Status | Sentences | Citation Grounding | Format / Tag Warnings | Probe Status |
|---|---|---:|---:|---:|---:|---|---|
| real_features | Gemini | PASS | PASS | 3 | yes | - | not applicable |
| real_features | Meta-Llama-3.1-8B-Instruct | FAIL | PARTIAL | 10 | yes | expected 3 sentences, got 10; invalid tag kind(s): Mechanism | not applicable |
| shuffled_features | Gemini | PASS | FAIL | 3 | yes | - | rationalizes shuffled feature |
| shuffled_features | Meta-Llama-3.1-8B-Instruct | FAIL | FAIL | 11 | yes | expected 3 sentences, got 11; invalid tag kind(s): Mechanism; normalized Evidence tag(s): WAS (7454) -> WAS | rationalizes shuffled feature |
| wrong_drug | Gemini | FAIL | FAIL | 3 | no | unexpected Evidence: UNC0638 | rationalizes mismatch |
| wrong_drug | Meta-Llama-3.1-8B-Instruct | FAIL | FAIL | 9 | yes | expected 3 sentences, got 9; normalized Evidence tag(s): COL11A1 (1301) -> COL11A1, MGP (4256) -> MGP | rationalizes mismatch |

## Interpretation

- **Real features:** Gemini passes the strict contract. Llama is **PARTIAL**: it copied the key IC50/tag evidence and did not introduce new numbers, but it ignored the exact 3-sentence constraint and used a non-contract `[Mechanism: ...]` tag.
- **Shuffled features:** both models fail the scientific probe because they give confident explanations from shuffled gene evidence instead of flagging the degraded input.
- **Wrong drug:** both models fail the scientific probe because they rationalize the substituted UNC0638 setup rather than detecting the metadata mismatch.

## Bottom Line For Slide

Gemini follows the requested output format better, but both Gemini and Llama are vulnerable to degraded-evidence probes. Llama 8B is especially weak on instruction following: it over-generates, uses non-contract tags, and sometimes includes Entrez IDs inside `[Evidence: ...]` tags.

## Responses

### Condition #2: real features

#### Gemini

A-204 Rhabdoid Cancer [Context: Disease] cells exhibit high sensitivity to AZD7762 due to the drug's mechanism as an inhibitor of checkpoint kinases 1 and 2 [Evidence: CHEK1;CHEK2], which are critical for cell cycle regulation often dysregulated in Rhabdoid Cancer [Context: Disease]. The AZD7762 chemical scaffold, acting as an inhibitor of checkpoint kinases 1 and 2 [Evidence: CHEK1;CHEK2], interacts with the cellular context of Rhabdoid Cancer [Context: Disease] where the aberrant activity of CHEK1 [Evidence: CHEK1] and CHEK2 [Evidence: CHEK2] is critical for cell cycle progression, a dependency potentially exacerbated by the high expression of MGP [Evidence: MGP] (z=+5.01, 100th pct) within the DNA damage response pathway. The A-204 cell line demonstrates high sensitivity to AZD7762 with a log₁₀(IC50) of -1.181 [Stats: Median_IC50], and exhibits high expression of MGP [Evidence: MGP] at 12.383 [Stats: Structural_Feature] (z=+5.01, 100th pct).

Adjusted status: **PASS**; strict pass: **PASS**.

#### Meta-Llama-3.1-8B-Instruct

1. The A-204 cell line's sensitivity to AZD7762 is likely due to the drug's inhibition of CHEK1;CHEK2, which are key checkpoint kinases involved in DNA damage response pathways that are often dysregulated in Rhabdoid Cancer [Context: Disease]. This mechanism is consistent with the drug's intended action as an inhibitor of checkpoint kinases 1 and 2 [Mechanism: inhibitor of checkpoint kinases 1 and 2].

2. The chemical scaffold of AZD7762, which targets CHEK1;CHEK2, may interact with the Gene Expression Features of A-204 cells by binding to the CHEK1;CHEK2 proteins, thereby inhibiting their activity [Stats: Structural_Feature]. This interaction may be facilitated by the high expression levels of CHEK1;CHEK2 in A-204 cells, as evidenced by the strong similarity between the gene expression profiles of A-204 and the E-106 evidence item [Stats: Similarity]. The resulting inhibition of CHEK1;CHEK2 activity may disrupt the DNA damage response pathway, leading to increased sensitivity to AZD7762 [Stats: Neighbor_Count].

3. The A-204 cell line shows a high sensitivity to AZD7762, with a log₁₀(IC50) value of -1.181 [Stats: Median_IC50], indicating that the drug is effective at low concentrations. This sensitivity is consistent with the strong evidence for CHEK1;CHEK2 inhibition, as seen in the E-106 evidence item [Evidence: CHEK1;CHEK2] [Stats: Similarity].

Adjusted status: **PARTIAL**; strict pass: **FAIL**.

### Condition #3: shuffled features

#### Gemini

A-204 Rhabdoid Cancer [Context: Disease] cells exhibit high sensitivity to AZD7762, an inhibitor of CHEK1;CHEK2 [Evidence: CHEK1;CHEK2], likely due to inherent cell cycle vulnerabilities characteristic of Rhabdoid Cancer [Context: Disease] biology that increase reliance on checkpoint kinases. The inhibitory mechanism of AZD7762 [clinical] on CHEK1;CHEK2 [Evidence: CHEK1;CHEK2] [Stats: Structural_Feature] interacts with the cellular context of A-204, where high expression of WAS [Evidence: WAS] (11.571 [Stats: Similarity], z=+5.02 [Stats: Similarity]) may contribute to cell cycle dysregulation, making the cells highly dependent on intact checkpoint kinase activity for survival. This high sensitivity is quantified by a log₁₀(IC50) of -1.181 [Stats: Median_IC50], and is further supported by the significant overexpression of WAS [Evidence: WAS] at 11.571 [Stats: Similarity] (z=+5.02 [Stats: Similarity], 100th pct).

Adjusted status: **FAIL**; strict pass: **PASS**.

#### Meta-Llama-3.1-8B-Instruct

1. The A-204 cell line's sensitivity to AZD7762 is likely due to the overexpression of CHEK1 and CHEK2, which are the targets of the drug, in the context of Rhabdoid Cancer [Context: Disease], a type of kidney lineage cancer. This overexpression may lead to an increased reliance on the CHEK1 and CHEK2 pathways, making the cells more susceptible to inhibition by AZD7762 [Evidence: CHEK1;CHEK2]. The drug's mechanism as an inhibitor of checkpoint kinases 1 and 2 [Mechanism: inhibitor of checkpoint kinases 1 and 2] would then effectively disrupt these pathways, leading to the observed sensitivity.

2. The chemical scaffold of AZD7762 [Stats: Structural_Feature] interacts with the gene expression features of A-204 by targeting the CHEK1 and CHEK2 genes, which are overexpressed in this cell line. This interaction is likely facilitated by the drug's mechanism as an inhibitor of checkpoint kinases 1 and 2 [Mechanism: inhibitor of checkpoint kinases 1 and 2], allowing it to bind to and inhibit the CHEK1 and CHEK2 proteins. The resulting disruption of the CHEK1 and CHEK2 pathways would then lead to the observed sensitivity.

3. The A-204 cell line shows a log₁₀(IC50) of -1.181, indicating a highly sensitive response to AZD7762 [Stats: Median_IC50]. This sensitivity is supported by evidence from E-101 [Evidence: WAS (7454)] with a z-score of +5.02 and 100th percentile, indicating a strong similarity between the WAS gene and the drug target CHEK1;CHEK2 [Stats: Similarity].

Adjusted status: **FAIL**; strict pass: **FAIL**.

### Condition #4: wrong drug

#### Gemini

The intermediate sensitivity of A-204 [Context: Disease] to UNC0638, an inhibitor of EHMT1 [Evidence: EHMT1] and EHMT2 [Evidence: EHMT2] methyltransferases, suggests that Rhabdoid Cancer [Context: Disease] cells may be vulnerable to epigenetic modulation, potentially through the disruption of histone methylation patterns critical for tumor cell survival. The UNC0638 [Evidence: UNC0638] chemical scaffold [Stats: Structural_Feature], acting as an inhibitor of EHMT1 [Evidence: EHMT1] and EHMT2 [Evidence: EHMT2] methyltransferase, interacts with the A-204 [Context: Disease] gene expression features, such as the high expression of MGP [Evidence: MGP] (z=+5.01), suggesting that the drug disrupts epigenetic regulation critical for maintaining the aberrant gene expression profile or survival pathways in Rhabdoid Cancer [Context: Disease]. A-204 [Context: Disease] exhibits an intermediate sensitivity to UNC0638 with a log₁₀(IC50) of 1.121 [Stats: Median_IC50], coinciding with the high expression of MGP [Evidence: MGP] at 12.383 (z=+5.01).

Adjusted status: **FAIL**; strict pass: **FAIL**.

#### Meta-Llama-3.1-8B-Instruct

1. The A-204 cell line's sensitivity to UNC0638 is likely due to the drug's inhibition of EHMT1 and EHMT2, which are involved in the regulation of gene expression and epigenetic modification in Rhabdoid Cancer cells [Context: Disease]. EHMT1 and EHMT2 are known to play a crucial role in the development and progression of Rhabdoid Cancer, suggesting that targeting these enzymes with UNC0638 may be an effective therapeutic strategy [Evidence: EHMT1;EHMT2].

2. The chemical scaffold of UNC0638, as an inhibitor of EHMT2 and GLP methyltransferase, interacts with the Gene Expression Features of A-204 cells by modulating the expression of genes involved in cellular processes such as collagen production [Stats: Structural_Feature] and cell proliferation [Stats: Structural_Feature]. This interaction may lead to changes in the cellular context, including the upregulation of genes such as COL11A1 [Evidence: COL11A1 (1301)] [Stats: Similarity], which is associated with a high similarity value of 11.733 [Stats: Similarity].

3. The observed sensitivity of A-204 cells to UNC0638, with a log₁₀(IC50) of 1.121 [Stats: Median_IC50], is supported by the pre-computed evidence, including the high similarity value of 12.383 [Stats: Similarity] for the gene MGP [Evidence: MGP (4256)]. Additionally, the inhibitor of EHMT2 and GLP methyltransferase, UNC0638, targets the drug target EHMT1;EHMT2, which is involved in the regulation of gene expression and epigenetic modification in Rhabdoid Cancer cells [Evidence: EHMT1;EHMT2].

Adjusted status: **FAIL**; strict pass: **FAIL**.
